Bio-Rad Laboratories, Inc. (BIO): Price and Financial Metrics
Bio-Rad Laboratories, Inc. (BIO)
Today's Latest Price: $581.71 USD
Updated Oct 23 7:00pm
Add BIO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
BIO Stock Summary
- BIO has a market capitalization of $16,602,973,886 -- more than approximately 89.2% of US stocks.
- BIO's went public 34.83 years ago, making it older than 92.9% of listed US stocks we're tracking.
- Price to trailing twelve month operating cash flow for BIO is currently 40.06, higher than 90.93% of US stocks with positive operating cash flow.
- Stocks that are quantitatively similar to BIO, based on their financial statements, market capitalization, and price volatility, are FTV, CERN, RDY, TFX, and XYL.
- Visit BIO's SEC page to see the company's official filings. To visit the company's web site, go to www.bio-rad.com.
BIO Stock Price Chart Interactive Chart >
BIO Price/Volume Stats
| Current price | $581.71 | 52-week high | $586.20 |
| Prev. close | $579.04 | 52-week low | $309.38 |
| Day low | $574.03 | Volume | 99,642 |
| Day high | $586.20 | Avg. volume | 224,708 |
| 50-day MA | $523.59 | Dividend yield | N/A |
| 200-day MA | $450.74 | Market Cap | 17.26B |
Bio-Rad Laboratories, Inc. (BIO) Company Bio
Bio-Rad Laboratories manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The company was founded in 1952 and is based in Hercules, California.
BIO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $581.71 | $163.08 | -71% |
Below please find a table outlining a discounted cash flow forecast for BIO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bio-Rad Laboratories Inc ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for BIO, they are:
- The company's debt burden, as measured by earnings divided by interest payments, is 109.99; that's higher than 96.74% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 12.58% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- BIO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 46.2% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -71% |
| 1% | -71% |
| 2% | -71% |
| 3% | -71% |
| 4% | -70% |
| 5% | -70% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BIO, try NRC, ABT, AZN, BAX, and GMED.
Loading social stream, please wait...